Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins (Q35068768)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Epstein–Barr virus

0 references

0 references

membrane protein

1 reference

based on heuristic

inferred from title

11

object named as

Barbara Pro

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

9

object named as

Luis Fayad

0 references

Catherine M Bollard

1

object named as

Catherine M Bollard

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Cliona M Rooney

20

object named as

Cliona M Rooney

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Malcolm Brenner

18

object named as

Malcolm K Brenner

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

19

object named as

Helen E Heslop

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

17

object named as

Adrian P Gee

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

8

object named as

Carlos Ramos

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

4

object named as

Oumar Diouf

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Elizabeth J Shpall

10

object named as

Elizabeth J Shpall

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

7

object named as

George Carrum

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

6

object named as

Yasmin Hazrat

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jack Meng-Fen Su

13

object named as

Meng-Fen Wu

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Stephen Gottschalk

2

object named as

Stephen Gottschalk

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

object named as

Vicky Torrano

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Andrea M Sheehan

15

object named as

Andrea M Sheehan

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Stephanie Ku

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Hao Liu

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Daniel Lee

14

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Youli Zu

16

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

16 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

798-808

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

New response criteria for lymphomas in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

HIV infection and lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Adoptive immunotherapy for cancer: building on success

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Epstein-Barr virus: 40 years on

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Central memory and effector memory T cell subsets: function, generation, and maintenance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Progressive differentiation and selection of the fittest in the immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Release of infectious Epstein-Barr virus by transformed marmoset leukocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

8 July 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

27 September 2018

Peptide length-based prediction of peptide-MHC class II binding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

27 September 2018

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

27 September 2018

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

27 September 2018

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

27 September 2018

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

27 September 2018

Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

27 September 2018

Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3940538

27 September 2018

Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24344220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/24344220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

https://pubmed.ncbi.nlm.nih.gov/24344220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Donor T cells to treat EBV-associated lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24344220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody successes in the clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/24344220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.51.5304

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35068768&oldid=2059987899"